In sum, these experiments gave proof-of-principle evidence that a pooled CRISPR-Cas9 genetic screen could be coupled to FACS-based isolation of low mCherry cells in order to identify genes that support HIF2A expression in ccRCC. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.